OAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Fredrik Schjesvold; Meletios A Dimopoulos; Sosana Delimpasi; Pawef Robak; Daniel Coriu; Wojciech Legieć; Luděk Pour; Ivan Špıčka; Tamás Masszi; Vadim Doronin; Jiří Minařík; Galina Salogub; Yulia Alexeeva; Antonio Lazzaro; Vladimír Maisnar; Gábor Mikala; Victoria Moody; Marcus Thuresson; Catriona Byrne; Johan Harmenberg; Roman Hájek; María‐Victoria Mateos; Paul G. Richardson; Pieter Sonneveld

doi:10.1016/s2152-2650(21)02124-8

Article2023

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Fredrik Schjesvold, Meletios A Dimopoulos, Sosana Delimpasi, Paweł Robak, Daniel Coriu, Wojciech Legieć, Luděk Pour, Ivan Špıčka, Tamás Masszi, Vadim Doronin, Jiří Minařík, Galina Salogub, Yulia Alexeeva, Antonio Lazzaro, Vladimír Maisnar, Gábor Mikala, Stefan Norin, Marcus Thuresson, A. Bergan, Jakob Obermüller, Roman Hájek, María‐Victoria Mateos, Paul G. Richardson, Pieter Sonneveld

Article2021

OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed/Refractory Multiple Myeloma (RRMM) - Impact of Prior Treatments Analysis

Meletios A Dimopoulos, Fredrik Schjesvold, María‐Victoria Mateos, Paweł Robak, Roman Hájek, Paul G. Richardson, Jakob Lindberg, Marcus Thuresson, Kajsa Larsson, Pieter Sonneveld

Article2017

A multicenter, randomized, phase 3 study of pomalidomide and dexamethasone (Pom-dex) with or without daratumumab in patients with relapsed or refractory multiple myeloma (RRMM): APOLLO

Evangelos Terpos, Meletios A Dimopoulos, Efstathios Kastritis, Jordan M. Schecter, Jon Ukropec, Elena Smith, Pieter Sonneveld

Article2018

Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).

Pieter Sonneveld, Evangelos Terpos, Meletios A Dimopoulos, Jon Ukropec, Elena Smith, Nienke Houkes, Jordan M. Schecter, Efstathios Kastritis

Article2013

Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003.

Hartmut Goldschmidt, Meletios A Dimopoulos, Katja Weisel, Philippe Moreau, Martha Q. Lacy, Kevin Song, Michel Delforge, Lionel Karlin, Anne Banos, Albert Oriol Rocafiguera, Xin Yu, Lars Sternås, Christian Jacques, Mohamed H. Zaki, Jesús F. San Miguel

OAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Discussion(0)

Related publications

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed/Refractory Multiple Myeloma (RRMM) - Impact of Prior Treatments Analysis

A multicenter, randomized, phase 3 study of pomalidomide and dexamethasone (Pom-dex) with or without daratumumab in patients with relapsed or refractory multiple myeloma (RRMM): APOLLO

Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).

Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003.